Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […]
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2020
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2020 The Lupus Research Alliance’s vision is a world free of lupus – by finding ways to prevent, treat and one day cure this disease. We work diligently to forge appropriate relationships with members of the pharmaceutical and biotech industries that share our vision and […]
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2021
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2021 The Lupus Research Alliance’s vision is a world free of lupus – by finding ways to prevent, treat and one day cure this disease. We work diligently to forge appropriate relationships with members of the pharmaceutical and biotech industries that share our vision and […]
LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting
Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […]
Lupus Research Alliance Grants Lupus Innovation Awards to Advance Ground-Breaking Lupus Research
New York, NY, March 23, 2023. The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants. Collectively, the seven projects led by research teams from the U.S. and Europe explore multiple components of lupus, focusing on its causes and the development of more personalized approaches to lupus treatments. […]
Lupus Research Alliance Announces 11 Exceptional Recipients of the 2021 Lupus Innovation Award
NEW YORK, NY, December 14, 2021. The Lupus Research Alliance proudly announced today recipients from the U.S. and around the world of the 2021 Lupus Innovation Award which will fund wide ranging areas of research from probing the development and progression of lupus to pointing to potential personalized therapies. The Lupus Innovation Award provides support […]
LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA
NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […]
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
NEW YORK, N.Y. — October 17, 2023: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory […]
Lupus Research Alliance Announces New Grants For Translational Research
Jan. 10, 2018 Lupus Research Alliance Announces New Grants for Translational Research Seven Outstanding Investigators Chosen for Prestigious Lupus Research Grants The Lupus Research Alliance is proud to announce the recipients of its Target Identification in Lupus (TIL) grants designed to move research discoveries quickly from the laboratory to the patient’s bedside. Seven outstanding scientists […]
LRA-BMS Accelerator Awards (BMS)
The LRA-BMS Accelerator Award ($300,000 for 2 years) is a collaborative project with sponsoring partner Bristol Myers Squibb supporting research on understanding human lupus heterogeneity and identifying novel biomarkers. If you are a researcher and would like to learn more about our funded research please click here.